Trials / Completed
CompletedNCT05320120
Investigation of Intranasal Ketamine Related Changes in Attentional Brain Networks With Functional and Structural MRI
Investigation of Intranasal Ketamine Related Changes in Attentional Brain Networks With Functional and Structural MRI: a Placebo Controlled, Randomized, Cross-over Trial
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 33 (actual)
- Sponsor
- Rupert Lanzenberger · Academic / Other
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
Subanesthetic ketamine is currently used as a rapid-acting antidepressant. It is an antagonist of the N-methyl-d-aspartate (NMDA) receptor, but former results indicate that its action also depends on the noradrenaline system and the locus coeruleus (LC). Based on this known impact of ketamine on the sympathetic nervous system the aim of this study is to investigate the effects of intranasal esketamine on LC related attentional brain networks in task based functional MRI, to relate those attention network changes to behavioural measures and to predict ketamine related attention network changes by brain structure.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 56mg esketamine (2x Spravato® 28 mg nasal spray) | 56mg esketamine (2x Spravato® 28 mg nasal spray) |
| DRUG | 0.9% saline solution nasal spray | 0.9% saline solution nasal spray |
Timeline
- Start date
- 2022-06-01
- Primary completion
- 2023-06-21
- Completion
- 2023-06-21
- First posted
- 2022-04-11
- Last updated
- 2024-04-15
Locations
1 site across 1 country: Austria
Source: ClinicalTrials.gov record NCT05320120. Inclusion in this directory is not an endorsement.